Ovarian cancer care: it's time for "personalized" approaches.
Aletti
Giovanni D
GD
Division of Gynecologic Oncology, European Institute of Oncology, Milan, Italy.
Hartmann
Lynn C
LC
D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D018394:CA-125 Antigen / Q000097:blood; D016190:Carboplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008565:Membrane Proteins / Q000097:blood; D009375:Neoplasms, Glandular and Epithelial / Q000175:diagnosis / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D018579:Patient Selection
D015415:Biomarkers; D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins; D004317:Doxorubicin; D016190:Carboplatin; D017239:Paclitaxel